IslandPass

Island Pharmaceuticals is a clinical-stage biotechnology company focused on repurposing existing drugs to address unmet needs in infectious diseases, particularly mosquito-borne viral infections. The company's lead program, ISLA-101, is a repurposed small molecule (fenretinide) currently being evaluated in the Phase 2a PEACH clinical trial for the prevention and treatment of Dengue fever. Island leverages its proprietary IslandPass platform, a rapid-response clinical trial framework designed to accelerate the development of antiviral therapies for emerging viral threats. Recently, the company expanded its pipeline by acquiring rights to Galidesivir, a broad-spectrum antiviral candidate with potential applications in filoviruses like Ebola. By utilizing drugs with established safety profiles, Island aims to significantly reduce the time and cost associated with traditional drug development.